Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
about
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatmentBreast cancer brain metastases: the last frontierHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsEmerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancerCurrent approaches to the treatment of metastatic brain tumours.Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.Central nervous system cancersTriterpenoids as potential agents for the chemoprevention and therapy of breast cancer.Promising molecular targeted therapies in breast cancerEfficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study.Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis.Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.Preclinical approaches to study the biology and treatment of brain metastases.The challenge of durable brain control in patients with brain-only metastases from breast cancer.Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.Breast cancer brain metastases: new directions in systemic therapyRadiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells.Breast cancer brain metastases: a review of the literature and a current multidisciplinary management guideline.Lapatinib and breast cancer: current indications and outlook for the future.Lapatinib for breast cancer: a review of the current literature.Chemoprevention for brain metastases.Recent developments in treatment stratification for metastatic breast cancer.Emerging drugs in metastatic breast cancer: an update.Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.The possibility of lapatinib treatment for breast cancer patients with central nervous system metastases. Case study and literature review.Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts.The role of systemic and targeted therapies in brain metastases.Brain metastases in breast cancer.Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.Systemic treatment of brain metastases in HER2-positive breast cancer: current status and future directions.Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the AnatolianEfficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.Current chemotherapeutic regimens for brain metastases treatment.Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review.Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
P2860
Q26751008-15D2C35A-880F-4F91-A4E5-FEF48CC26DD0Q26775663-41B1B077-842B-420B-8FD0-8F776589D3FFQ26777681-FDF7B288-BABD-430F-A76A-54122A21A9C2Q26824799-221BE3BC-114D-41B6-BA1C-0AAB71FE1EF0Q33696559-8FCD5117-F102-4A8C-A4E7-0F55244B2F5AQ33777436-690C9076-3FF8-4CD2-9805-FB9D664C6426Q34014740-C87DBEF4-0CD2-4C51-B740-201C4B9478D7Q34675534-FE82C8A5-2D3D-4934-AD29-CC8E426FB2E7Q35040295-52669E12-C36B-40AF-A0A7-F49CAD6BC64CQ35092651-08D088AC-FF40-4D90-8672-47454AD585D4Q35313640-4323B98D-9CE0-4949-8A11-83820ECE52C9Q35687574-1A33413E-FD06-40F7-8865-E68DEF260420Q35967411-EED909C4-BEA3-4868-B806-704F1187C9E3Q36234038-1D60B747-58E8-4D0E-B4AB-C2F15D1BF841Q36287951-A1EB8BDA-A87B-40C0-AD33-BF7E9C5FE028Q36371783-F1A4A04A-75A7-4DAE-BC14-95401D06BDCFQ36822500-B7CB73A1-782A-4C8F-9F09-75414BC338A9Q37694756-C5824B7A-77DE-422B-A2F9-148FD4234C8DQ37698300-B2FA5096-3C93-4D7B-9BB5-7801F7CF2176Q37782086-0CFA7A04-92EB-45D8-B9BB-F54540E60F9EQ37810946-C6511E5B-2378-4488-ACFE-EBF6056D92E3Q37946748-1D963C0B-41CF-418A-B712-FCFE59DD1A34Q37950515-FCF75260-C88C-4B44-A22B-6DC204FE6145Q37961957-7E18FF38-9FA3-41A7-AF9A-CAD161A1B2ECQ38064719-3E379370-2C82-4A5D-BCC9-84DD503A77B0Q38116009-00D1ACD4-7002-40D8-B733-808CD550DBB0Q38155202-43245295-99D0-4456-A436-E012339E5084Q38168919-C0AE23AB-4A04-4426-98B8-E99779B9081BQ38168924-24300FA2-0B70-468F-81CB-54A1C8CF2448Q38829087-9A89507B-A1F7-4647-A26B-44224A4370CEQ39652258-F704C75B-F121-4810-84BD-E4994EB66369Q44134898-6E8C5AEA-5749-401A-9676-4A670C01A44BQ44417765-58EA7726-4DDD-4ECF-98F2-3CEBFC92C5CDQ44625585-1076C87F-ADCE-461A-9C58-3008D2982F88Q47793228-6CF24273-5107-4FE2-8D6F-064EFB2CD510Q47839509-3DD9C8BB-E277-4505-AAEE-953AFB9DE9D6Q48106837-B51BB455-0FC6-4AE1-8BE7-DA5A3867EBCFQ48109517-237146C0-BE19-44B8-A75D-541F7D950ED5Q48162978-8452D48C-4D2C-47FD-99AE-3FF4731A226FQ48404872-9E112332-A93C-471A-B50C-28E78B5E3BCD
P2860
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Treatment of HER2-positive met ...... metastases--the UK experience.
@ast
Treatment of HER2-positive met ...... metastases--the UK experience.
@en
type
label
Treatment of HER2-positive met ...... metastases--the UK experience.
@ast
Treatment of HER2-positive met ...... metastases--the UK experience.
@en
prefLabel
Treatment of HER2-positive met ...... metastases--the UK experience.
@ast
Treatment of HER2-positive met ...... metastases--the UK experience.
@en
P2093
P2860
P356
P1476
Treatment of HER2-positive met ...... metastases--the UK experience
@en
P2093
N Davidson
S R D Johnston
S Sutherland
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605586
P407
P577
2010-02-23T00:00:00Z
P5875
P6179
1004080397